论文部分内容阅读
目的观察个体化治疗-胰岛素泵持续皮下输注胰岛素(CSII)联合动态血糖监测系统(CGMS)在2型糖尿病强化治疗中的应用价值。方法 2型糖尿病患者共72例,按前瞻、随机、盲法、对照分为A、B、C3组,A组为个体化治疗组(CSII)联合(CGMS),B组、C组为对照组,分别应用胰岛素泵和多次胰岛素皮下注射,均配合指血监测,观察指标为FBG与2hPG变化、血糖达标(FBG<7.0mmol/L,2hPG<10.0mmol/L)时间、低血糖(血糖<3.9mmol/L)发生率。结果 3组强化治疗2周后,空腹血糖、餐后血糖均较治疗前明显下降,差异有统计学意义(P<0.01),3组间血糖比较差异无统计学意义(P>0.05),个体化治疗组血糖达标快,时间短,低血糖发生率低,差异有统计学意义(P<0.01)。结论个体化治疗组患者应用CGMS可优化治疗方案,血糖达标时间短,强化治疗达标率高,低血糖发生率显著减少。
Objective To observe the value of personalized therapy - continuous subcutaneous infusion of insulin pump (CSII) combined with ambulatory blood glucose monitoring system (CGMS) in intensive treatment of type 2 diabetes mellitus. Methods A total of 72 patients with type 2 diabetes mellitus (T2DM) were randomly divided into A, B and C3 groups according to prospective, randomized and blinded methods. Group A was treated with CSII combined with CGMS. Group B and C were control group , Respectively, the application of insulin pump and multiple subcutaneous injections of insulin, both with finger blood monitoring, the observation indicators for the FBG and 2hPG changes, blood glucose compliance (FBG <7.0mmol / L, 2hPG <10.0mmol / L) 3.9mmol / L) incidence. Results After 3 weeks of intensive treatment, fasting blood glucose and postprandial blood glucose were significantly lower than those before treatment (P <0.01). There was no significant difference in blood glucose between the three groups (P> 0.05) The treatment group had fasting blood glucose, short time, low incidence of hypoglycemia, the difference was statistically significant (P <0.01). Conclusion CGMS can optimize the treatment of patients in the individualized treatment group, the blood glucose compliance time is short, intensive treatment compliance rate, low incidence of hypoglycemia significantly reduced.